TNFRSF8/CD30 Antibody [G5N10] | Primary Antibodies

Application: Reactivity: Human, Monkey

Lane 1: HDLM-2, Lane 2: Karpas-299

Usage Information

Dilution
WB1:1000 IHC1:50 IF1:4000 FCM1:200-1:800

Application
WB, IHC, IF, FCM

Reactivity
Human, Monkey

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
90 kDa, 120 kDa

Datasheet & SDS

Biological Description

Specificity
TNFRSF8/CD30 Antibody [G5N10] detects endogenous levels of total TNFRSF8/CD30 protein.

Clone
G5N10

Synonym(s)
Tumor necrosis factor receptor superfamily member 8; CD30L receptor; Ki-1 antigen; Lymphocyte activation antigen CD30; CD30; TNFRSF8; D1S166E

Background
TNFRSF8, commonly known as CD30, belongs to the tumor necrosis factor receptor (TNFR) superfamily and functions as a type-I transmembrane glycoprotein that modulates immune cell activation and survival. It features an extracellular cysteine-rich domain for ligand binding and a cytoplasmic tail with distinct D1, D2, and D3 subdomains that recruit signaling adaptors. CD30 primarily signals through direct binding to TRAF2 and TRAF5 via its D2 domain, triggering two competing pathways: rapid TRAF2 degradation that sensitizes cells to apoptosis through caspase activation, and NF-κB canonical activation via IKK complex recruitment, leading to p65/RelA nuclear translocation and transcription of prosurvival genes like Bcl-xL and cytokine regulators. In anaplastic large cell lymphoma (ALCL) cells, CD30 stimulation induces TRAF2 downregulation and NF-κB impairment, promoting caspase-dependent cell death, whereas in Hodgkin lymphoma cells, constitutive low-level signaling maintains TRAF2 stability and sustains NF-κB activity to block apoptosis. This context-dependent duality arises from dosage effects and co-receptor interactions, with TACE-mediated ectodomain shedding further attenuating ligand-dependent responses by reducing surface CD30. CD30 fine-tunes T-cell expansion and B-cell maturation by balancing proliferation against programmed death, making it valuable for researchers dissecting TRAF-NF-κB crosstalk in lymphocyte fate decisions or immune checkpoint modulation. Its expression on activated lymphocytes supports normal germinal center reactions and memory formation, with regulatory control via JunB and NPM-ALK in pathologic states influencing therapeutic windows. Dysregulation through overexpression drives lymphomagenesis in Hodgkin and ALCL by sustaining oncogenic NF-κB, while fusion proteins amplify its prosurvival arm.

Background

TNFRSF8, commonly known as CD30, belongs to the tumor necrosis factor receptor (TNFR) superfamily and functions as a type-I transmembrane glycoprotein that modulates immune cell activation and survival. It features an extracellular cysteine-rich domain for ligand binding and a cytoplasmic tail with distinct D1, D2, and D3 subdomains that recruit signaling adaptors. CD30 primarily signals through direct binding to TRAF2 and TRAF5 via its D2 domain, triggering two competing pathways: rapid TRAF2 degradation that sensitizes cells to apoptosis through caspase activation, and NF-κB canonical activation via IKK complex recruitment, leading to p65/RelA nuclear translocation and transcription of prosurvival genes like Bcl-xL and cytokine regulators. In anaplastic large cell lymphoma (ALCL) cells, CD30 stimulation induces TRAF2 downregulation and NF-κB impairment, promoting caspase-dependent cell death, whereas in Hodgkin lymphoma cells, constitutive low-level signaling maintains TRAF2 stability and sustains NF-κB activity to block apoptosis. This context-dependent duality arises from dosage effects and co-receptor interactions, with TACE-mediated ectodomain shedding further attenuating ligand-dependent responses by reducing surface CD30. CD30 fine-tunes T-cell expansion and B-cell maturation by balancing proliferation against programmed death, making it valuable for researchers dissecting TRAF-NF-κB crosstalk in lymphocyte fate decisions or immune checkpoint modulation. Its expression on activated lymphocytes supports normal germinal center reactions and memory formation, with regulatory control via JunB and NPM-ALK in pathologic states influencing therapeutic windows. Dysregulation through overexpression drives lymphomagenesis in Hodgkin and ALCL by sustaining oncogenic NF-κB, while fusion proteins amplify its prosurvival arm.

References
https://pubmed.ncbi.nlm.nih.gov/9353251/ https://pubmed.ncbi.nlm.nih.gov/11110706/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%